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DC-SIGN, a lectin, which presents at the surface of immature dendritic cells, constitutes nowadays a 
promising target for the design of new antiviral drugs. This lectin recognizes highly glycosylated proteins 
present at the surface of several pathogens such as HIV, Ebola virus, Candida albicans, Mycobacterium 
tuberculosis, etc. Understanding the binding mode of this lectin is a topic of tremendous interest and 
will permit a rational design of new and more selective ligands. Here, we present computational and 
experimental tools to study the interaction of di- and trisaccharides with DC-SIGN. Docking analysis 
of complexes involving mannosyl di- and trisaccharides and the carbohydrate recognition domain 
(CRD) of DC-SIGN have been performed. Trisaccharides Mana1,2[Mana1,6]Man 1 and 
Mana1,3[Mana1,6]Man 2 were synthesized from an orthogonally protected mannose as a common 
intermediate. Using these ligands and the soluble extracellular domain (ECD) of DC-SIGN, NMR 
experiments based on STD and transfer-NOE were performed providing additional information. 
Conformational analysis of the mannosyl ligands in the free and bound states was done. These studies 
have demonstrated that terminal mannoses at positions 2 or 3 in the trisaccharides are the most 
important moiety and present the strongest contact with the binding site of the lectin. Multiple binding 
modes could be proposed and therefore should be considered in the design of new ligands. 
 
Introduction 
DC-SIGN (dendritic cell-speciﬁc ICAM-3 grabbing non-integrin) 
or CD209 is a C-type lectin expressed at the surface of im- 
mature dendritic cells. This lectin presents at the C-terminus a 
carbohydrate recognition domain (CRD) able to interact with 
highly glycosylated proteins found on several pathogens such as 
viruses (HIV-1 and 2, SIV-1, Ebola virus, HCV, SARS virus, 
cytomegalovirus, dengue virus); bacteria (Helicobacter pylori, 
Klebsiella pneumonae, Mycobacterium tuberculosis); yeast (Can- 
dida albicans); and parasites (Schistosoma mansoni, Leishmania 
pifanoi).1,2 This so broad spectrum of pathogens recognized by 
DC-SIGN has led to consider this lectin as an universal pathogen 
receptor. This lectin has attracted the interest of the scientiﬁc 
community since the discovery of the role that DC-SIGN plays 
in a HIV trans infection process.3 
Pathogen glycoproteins recognized by DC-SIGN contain 
mainly mannose and fucose carbohydrate structures as N- 
glycans at different Asn positions of the glycoproteins. High 
mannose structure, constituted by Man9GlcNAc2 as the main 
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epitope, is considered one of the strongest ligands for this lectin. 
Carbohydrate–protein interactions are selective, most of the time 
calcium dependent, and very weak. Nature overcomes this weak 
afﬁnity providing a multivalent presentation of carbohydrate 
epitopes such as cluster organization at the cell surface of glycosph- 
ingolipids and highly glycosylated glycoproteins. To study and 
intervene in biological processes where this type of interaction is 
involved, the design and preparation of multivalent carbohydrate 
systems is required. There is a continuing interest in designing new 
and effective multivalent tools. Selection of carbohydrate epitopes 
requires a deep knowledge of the binding mode of the ligands and 
the binding site of the protein receptor. Information about binding 
constants of monovalent and multivalent mannosyl and fucosyl 
oligosaccharides with DC-SIGN have been reported by different 
groups using a variety of techniques such as ELLA, biosensors, 
etc.4–11 However, to date only scarce information at the molecular 
level is available about how carbohydrates are recognized by DC- 
SIGN in solution. To our best knowledge, the only available 
information concerning carbohydrate ligands and DC-SIGN is at 
the solid state. X-Ray structures of complexes formed by different 
carbohydrate oligosaccharides with up to 9 units constituting part 
of the high mannose structure and CRD of DC- and L-SIGN 
have been recently published.12–14 Our interest on the receptor DC- 
SIGN lead us to explore in more detail the molecular basis of this 
recognition process with the aim to design and prepare appropriate 
ligands and their corresponding multivalent systems for potential 
applications in biological processes where DC-SIGN is involved. 
Also, available structural information about the binding process of 
carbohydrates to DC-SIGN indicates the possibility of different 
binding modes of these ligands. A preliminary study involving 
  
 
DC-SIGN and carbohydrate mimics has been published recently 
by some of us.15 
Here, we describe the use of computational (docking studies) 
and NMR (STD, and transfer NOE experiments) tools to get 
information about the binding mode of DC-SIGN ligands. Among 
the potential epitopes to be tested as ligands for DC-SIGN, we 
have analyzed two mannosyl trisaccharides. On one hand, these 
compounds represent a good choice as binding ligands (better 
than the simple mannose)  and  on  the  other  hand,  they  can 
be obtained with a reasonable synthetic cost. Because the high 
mannose structure consists of mannose units alinked by glycosidic 
bonds at positions 2, 3, and 6, we have selected two branched 
trisaccharides. The trisaccharide Mana1,2[Mana1,6]Man 1 and 
the trisaccharide Mana1,3[Mana1,6]Man 2. The trisaccharide 1 is 
not present in the high mannose structure, but it constitutes the 
repeated unit of the cell-wall mannans such as lipoarabinomannan 
(LAM) present in Mycobacterium tuberculosis which is recognized 
by DC-SIGN.16–19  The trisaccharide 2 is a fragment present in 
the high mannose responsible for the recognition process by DC- 
SIGN as has been described previously.12 
As a starting point for docking studies, we have used the crys- 
tallographic information already published. We have analyzed ﬁve 
selected ligands, the two trisaccharides above mentioned and the 
corresponding disaccharide moieties present in these molecules: 
Mana1,2Man, Mana1,3Man, and Mana1,6Man. Simultaneously, 
we have synthesized the two selected trisaccharides with a short 
linker at the anomeric position which will allow the attachment of 
these ligands to multivalent scaffolds afterwards. We have used 
an orthogonally protected mannose previously described as a 
common intermediate for the synthesis of the trisaccharides.20 
These mannosyl oligosaccharides have been used to test their 
binding behavior in the presence of the soluble extra-cellular 
domain (ECD) of DC-SIGN. The analysis of the binding process 
in solution has been performed using a series of NMR experiments 
directed to obtain structural data of the bound ligands. 
 
Results and discussion 
Docking analysis 
To  gain insight about the binding mode of DC-SIGN ligands,    
a docking study was carried out  considering  a representative 
set of mannosyl di- and trisaccharide structures. In particular, 
we selected for these computational studies the disaccharides 
Mana1,2Man, Mana1,3Man and Mana1,6Man, and the trisac- 
charides Mana1,3[Mana1,6]Man and Mana1,2[Mana1,6]Man. 
(Fig. 1) 
The docking of the proposed ligands into the DC-SIGN binding 
site was done using an automated docking procedure (FlexiDock) 
using the crystal structure data of the  complex  of  DC-SIGN 
and the pentasaccharide GlcNAc2Man3 (pdb code 1k9i). Those 
structures showing key distances or torsional angles inconsistent 
with experimental results were rejected. Then, the best solutions in 
terms of energy were energy-minimized prior to further analysis. 
The ﬁnal complexes were evaluated in terms of consensus of 
ligand–protein interactions and dihedral angles with the exper- 
imental data and the known values of energy interaction using the 
programs STC and DOCK module (SYBYL) (Table 1). Detailed 
information including key protein residues involved in the binding, 
 
 
 
Fig. 1 Chemical structures of the three disaccharides (Mana1,2Man, 
Mana1,3Man and Mana1,6Man), and the two trisaccharides 
(Mana1,3[Mana1,6]Man and Mana1,2[Mana1,6]Man) considered in the 
docking studies. 
 
the U/w conformational space, along with the distance to the Ca2+ 
(primary binding site) and the interprotonic distances are given in 
the supplementary information (Table S1 and Fig. S1–S20). 
Based on the crystal structure, it is possible to deﬁne two possible 
binding sites for disaccharides: a primary one containing the Ca2+ 
atom and an adjacent secondary one. We performed docking 
studies considering two possible sites for the a1–2 and a1–6-linked 
mannoses. In both cases, the most favoured binding mode (Table 1) 
is located at the primary site, presenting interactions with the Ca2+ 
atom; therefore, we focused on the binding at the primary site in 
subsequent studies. 
The docking study of Mana1,2Man led to three families of 
structures with two different binding modes (see supplementary 
information, Fig. S5–S8). In the less populated orientation (clus- 
ter 3) the reducing end side is bound to the Ca2+ ion at the primary 
binding site. The major orientation, where the non-reducing end 
of the disaccharide binds the Ca2+ atom (cluster 1 and cluster 2), 
corresponds to the best solution in terms of energy and geometry 
restrictions. It should be mentioned that recent crystallographic 
analysis of the complex formed by this disaccharide and DC-SIGN 
has shown multiple binding modes which have been postulated as 
a mechanism for increasing afﬁnity.14 All acceptable structures 
found for Mana1,6Man are mixtures of gg and gt conformers 
around the x torsion angle (see supplementary information, 
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Table 1 Dihedral angles and docking energy 
Complex U/w DGbind/kcal mol−1 Edock/kcal mol−1 
1d13 1→3: 65.2/144.8 −4.8 2.1 
1d16 1→6: 63.8/153.0 −5.3 −34.6 
2d16 1→6: 52.2/166.0 −2.2 −0.1 
1d12 1→2: 68.5/85.9 −5.9 −37.2 
2d12 1→2: 42.1/90.3 −5.6 −19.6 
1t36 1→3: 96.5/155.1 6←1: 68.7/181.4 −7.3 −55.0 
1t26 1→2: 81.4/168.0 6←1: 88.4/205.6 −6.7 −51.4 
 
 
Fig. S9–S11), although after energy-minimization the gg confor- 
mation (1d16) was found to be the most stable one (Fig. S12). The 
non-reducing end of the sugar chain binds to the Ca2+ atom in all 
the best solutions. The docking studies of Mana1,3Man yielded 
three possible families (see supplementary information, Fig. S1- 
S4). The most populated binding mode, which also had the best 
values of docking energy and DGbind, showed in all the solutions 
the non-reducing end of the sugar bounded to the Ca2+ atom (with 
a distance of the O3 atom to the calcium atom around 2.3 A˚ ) and 
glycosidic linkage torsions in accordance with the experimental 
angle ranges data for the linkage 1,3 ( 49 < U < 82 and 16 < 
w < 32) (Fig. S1). 
The complexes are stabilized by a large number of hydrogen 
bonds, which in the case of the disaccharide Mana1,3Man, were 
experimentally observed in the complex of DC-SIGN and the 
pentasaccharide GlcNAc2Man3 (see Table S1).
12 In addition to 
these interactions, the Ca2+ ion is bound by the equatorial 3- and 
4-hydroxyl groups of a mannose residue (see Table S1). A detailed 
description of relevant protein–ligand interactions, including C– 
H aromatic, is given in the supplementary information. The 
DGbind and the docking energy calculated with the STC and DOCK 
program respectively, suggest that the disaccharides with a1–2 and 
a1–6 type union are the best ligands for DC-SIGN (Table 1). These 
results are in agreement with the experimental values of binding 
published by Weis et al.12 
In the case of the trisaccharides, the FlexiDock analysis of the 
complex of Mana1,3[Mana1,6]Man with DC-SIGN led to a model 
that is very similar to that of the crystal structure (Fig. S13– 
S17). The a-1,2 linkage in Mana1,2[Mana1,6]Man is described 
by an ensemble of exo-anomeric conformers (U between 30  
and 60◦) compatible with the experimental data. The short 
distances between H1c and H2a, and between H1c and H1a 
observed for Mana1,2[Mana1,6]Man are in agreement with the 
NMR studies of this linkage (see supplementary information, 
Fig. S18–S22). The 1,6-glycosyl bonding in the trimannoside 
was found exclusively as gt conformers around the x torsion,   
in contrast to the mixture of  gg  and  gt  conformers  obtained 
for the 1,6-bonded structures of the dimannoside. The structural 
parameters of the ﬁnal complex of each trisaccharide and the 
energy of interaction are gathered in Table S1. The hydrogen 
bond network observed for the disaccharides is preserved  in 
both trisaccharide-complex models (Table S1). Both trisaccharides 
showed hydrophobic interaction between the ManC (1t26) and 
ManD (1t36) units and the residue Val 351. Aromatic interactions 
of both complexes with Phe 313 have also been found. In addition, 
the mannose ManA in Mana1,2[Mana1,6]Man complex displays 
a C–H · · · aromatic interaction (ach x= 160.2, dCX (A˚ ) = 4.0, dHpX 
(A˚ ) = 1.2). 
 
Ligand synthesis 
 
The trisaccharides Mana(1 3)[Mana(1  6)]Mana1OCH2CH2- 
NH2 2 and Mana(1 2)[Mana(1 6)]Mana1OCH2CH2NH2 1 
have been prepared using an orthogonally protected mannose 
derivative 8 as a common intermediate. This mannose derivative 8 
was prepared in 7 steps from 2-azidoethyl a-D-mannopyranoside 
(3) as shown in Scheme 1.20 
In a previous communication we have described the synthesis 
of compound 8 and the corresponding orthogonal deprotections 
at positions 2, 3 and 6.20 The hydroxyl group at position 6 was 
protected as a silyl group using tert-butyldiphenylsilyl chloride 
(TBDPSCl) and imidazole in DMF. A benzyl group was intro- 
duced at position 4 as a permanent protecting group (this position 
will not be glycosylated in this synthetic approach) using benzyl 
chloride and sodium hydride in DMF in 79%  yield.  For  this 
aim, the formation of an acetonide using 2,2j-dimethoxypropane 
and pyridinium p-toluenesulfonate (PPTS) in acetone was ﬁrst 
necessary to protect positions 2 and 3 simultaneously. After 
introducing the benzyl group at position 4, the acetonide was 
easily cleavage with TFA in dichloromethane at rt to give 
compound 5 in 63% yield over three steps. The hydroxyl group  
at position 3 was selectively protected as the p-methoxybenzyl 
(PMB) ether using a stannylene acetal intermediate as strategy. 
Reaction with dibutyltin oxide in toluene at reﬂux and then, 
PMBCl and tetrabutylammonium iodide (TBAI) gave a complete 
regioselective protection of that position giving compound 6 in 
good yield. Finally, a levulinoyl ester was used to protect position 
2 using levulinic acid and dicyclohexylcarbodiimide (DCC) in 
dichloromethane at rt affording the orthogonally protected man- 
nose 8 in 88% yield. 
Synthesis of trimannose 2 was accomplished using the mannose 
derivative 10 as central unit with free hydroxyl groups at positions 
3 and 6 (Scheme 2). This mannose 10 was prepared from 
orthogonally protected mannose 8 in two steps by cleavage of silyl 
group at position 6 with TBAF in THF at rt to afford mannose 
derivative 9 and following treatment with TFA at 20 ◦C in 
dichloromethane to remove selectively the PMB group at position 
3; mannose derivative 10 was obtained in 97% yield over two 
steps. (Scheme 1) A double glycosylation, using 2 equivalents 
of thiophenyl mannopyranoside 13 (previously described by our 
group)21 as glycosyl donor, N-hydroxysuccinimide (NHS) and 
triﬂic acid as promoter, gave the protected trisaccharide 11 in 
78% yield. Two deprotections steps with NaOMe in methanol 
to remove acetate and levulinate groups and hydrogenation 
using Pd on carbon as catalysts in methanol to remove benzyl 
groups and reduce the azide gave trisaccharide 2 in good yield. 
(Scheme 2). 
  
 
 
 
Scheme 1 Synthesis of orthogonally protected mannose derivative 8 and selective deprotections. Reagents and conditions: a) TBDPSCl, Im, DMF, rt, 
79%; b) 2,2j-dimethoxypropane, PPTS, acetone; then, BnCl, NaH, DMF, 0 ◦C to rt; then, TFA DCM, rt 63% over 3 steps; c) Bu2SnO, Tol, D; then, 
PMBCl, Bu4NI, D, 82%; d) DCC, LevOH, DCM, rt, 88%; e) TBAF, THF, rt, 95%; f) AcOH, THF, 0 ◦C to rt, then, TBAF, 100%; g) TFA, DCM, −20 ◦C, 
97%. 
 
 
Scheme 2 Synthesis of Mana1–3[Mana1–6]Man 2. Reagents and con- 
ditions:  a)  13  (2  equiv.),  4  A˚   MS,  NIS,  TfOH,  −20  ◦C,  DCM,  78%; 
b) NaOMe, MeOH, rt; c) H2, Pd-C, MeOH, rt, 100%. 
 
 
Trisaccharide 1 was prepared starting from mannose derivative 
7. This trisaccharide was synthesized in three steps as shown in 
Scheme 3. Mannose derivative 7 was prepared from mannose 
6 removing silyl group at position 6 with TBAF in THF at rt 
(Scheme 1). Following the same methodology used for trimannose 
11, the trisaccharide 12 was obtained in 70% yield using 2 
equivalents of mannosyl donor 13, NHS and triﬂic acid. Again, 
two deprotection steps were needed to prepare 1 using NaOMe 
in methanol and catalytic hydrogenation with Pd on carbon in 
methanol. In this way, trisaccharide 1 was obtained in good yield. 
Both trisaccharides 1 and 2 show at the anomeric position an 
adequate linker with a terminal amine allowing their attachment 
to multivalent scaffolds to create carbohydrate multivalent tools. 
All new compounds described above were fully characterized using 
NMR and mass spectrometry. 
 
Scheme 3 Synthesis of Mana1–2[Mana1–6]Man 1. Reagents and con- 
ditions:  a)  13  (2  equiv.),  4  A˚   MS,  NIS,  TfOH,  −20  ◦C,  DCM,  70%; 
b) NaOMe, MeOH, rt; c) H2, Pd-C, MeOH, rt, 100%. 
 
 
 
Structural analysis 
The basic structures of trisaccharides 1 and 2 are present in a 
wide variety of natural compounds from high mannose to GPI 
structures which have been extensively studied, and their 3D 
structures have been described both isolated or as part of larger 
oligosaccharides,21 and their conformational maps described in 
several structural databases such as Heidelberg and CERMAV.22 
The interaction of trisaccharides 1 and 2 with DC-SIGN was 
studied by STD (saturation transfer difference) techniques deter- 
mining their interaction epitopes.23,24 The bound conformations 
of trisaccharides 1 and 2 were also deduced from transfer-NOE 
experiments registered in presence of DC-SIGN ECD.25 
  
 
 
Trisaccharide Mana1,2[Mana1,6]Man 1. The relative impor- 
tance of each mannose  unit  in  the  binding  process  to  DC-  
SIGN was assessed by means of STD experiments. Several 
saturation times were used in order to avoid potential interferences 
from differences of longitudinal relaxation of the ligand protons  
and thus, to ensure the consistency of the results. The relative STD 
effects are shown on Fig. 2. The larger effects are concentrated     
on the 1–2 linked residue, the mannose-C, followed by the other 
terminal one, mannose-B, while the central one shows the lowest 
effects. These results could be explained based on a folded 
conformation where the terminal residues contact with the lectin    
or by the existence of several binding modes. 
 
Fig. 2 STD experiment of 1 in the presence of DC-SIGN recorded with 
2.5 s of saturation time and absolute and relative STD values for key 
signals. 
 
The conformation of 1 bound to DC-SIGN was studied by 
transfer NOE experiments. In the presence of 2% of the lectin, 
the sign of the NOE peaks was inverted (see Fig. 3) indicating 
ligand–receptor binding at favourable rate. The pattern of NOEs 
and their growing rates were not indicative that the conformation 
in the bound state was essentially similar  to  the  free  ligand 
(see supplementary information). The Man 1–2 linkage can be 
described mainly as an ensemble of exo-anomeric conformers with 
a signiﬁcant degree of ﬂexibility about the w angle, which shows 
two relative minima. The observation of a weak NOE between H2c 
and H1a could be indicative of an increase of the population of 
 
 
 
Fig. 3 Expansion of the NOESY experiments of 1, free (top) and in the 
presence of 1 : 50 molar of DC-SIGN (bottom), showing the NOE peaks 
representative of the conformation of the glycosidic linkages. Experiments 
registered at 500 MHz, in 150 mM NaCl, 20 mM TRIS-d6  4 mM CaCl2 
at 278 K using a mixing time of 600 ms for free and 400 ms in presence of 
DC-SIGN. 
 
non-exoanomeric conformers for the 1–2 linkage compared with 
the free state. The NOEs between H1b and H6ja and H6jja were 
clearly observed, in accord with the trans disposition of the w 
torsion. Unfortunately, the data regarding the 1–6 linkage were 
not conclusive with respect to the determination of the x rotamer. 
 
Trisaccharide Mana1,3[Mana1,6]Man 2. The STD experi- 
ments for 2 were also conclusive with respect to the interaction 
between the trisaccharide and DC-SIGN, and clear peaks due to 
magnetization transfer were observed. Interestingly, the overall 
magnitude of the absolute STD effects was larger than that 
observed for the trisaccharide 1. The relative STD values were 
higher for  the 1–3 linked ManD, suggesting that this unit has    
a stronger interaction with the lectin (Fig. 4). In this case, the 
terminal residue ManB has a lower transference than the central 
one, suggesting small differences in the binding mode between 
both trisaccharides. The absolute STD values of both samples 
(Table 2) can be compared considering the similar  nature  of 
both compounds, the equivalence in concentration and in the 
ratio ligand to protein for both samples and that the dissociation 
constant can be estimated to be near high millimolar. In these 
 
Table 2 Relative and absolute STD values for 1 and 2 
 
 
STD Abs (1) STD Rel STD Abs (2) STD Rel 
H1–A 1.86 29.68 6.12 60.16 
H2–A 2.38 38.08 5.42 63.32 
H4–A 2.94 47.04 6.00 70.09 
H6–A 2.16 34.56 3.07 35.86 
CH2O2–A nd — 4.57 53.33 
H1–B 2.51 40.16 3.82 44.63 
H2–B 2.57 41.12 5.38 62.85 
H3–B 3.09 49.36 6.11 71.38 
H1–C or D 3.10 49.60 5.05 58.94 
H2–C or D 6.25 100.00 8.56 100.00 
H4–C or D 3.38 54.00 8.47 98.89 
H5–C or D nd — 6.33 73.89 
H6–C or D 4.12 65.84 7.13 83.29 
  
 
 
 
Fig. 4 STD experiment with 2 in presence of DC-SIGN recorded with 
2.5 s of saturation time and absolute and relative STD values for signiﬁcant 
signals. 
 
conditions, the higher STD observed for 2 could be indicative of 
stronger binding than 1.24 
The transfer NOESY experiments of trisaccharide 2 registered 
in the presence of DC-SIGN ECD showed negative NOEs 
indicative of transient binding of the carbohydrate to the lectin 
(Fig. 5). The observed differences between equivalent experiments 
of 2, free or with DC-SIGN, are due to the expected changes in 
the linewidth and correlation times. A more quantitative analysis 
based on the NOE growing rate does not evidence changes on key 
interprotonic distances (supplementary information) indicating 
that the relative orientation of the monosaccharidic rings is nearly 
the same as in the free compound, and no major conformational 
changes can be detected upon binding. Then the 1–3 linkage is 
mainly in a syn-w disposition at U angles compatible with the 
exo-anomeric effect, and the 1–6 linkage is in a trans disposition 
regarding the w torsion but the x rotamer could not be deﬁned. 
 
Conclusions 
Herein, we have described a combined approach based on 
docking analysis, synthesis and NMR to study the interaction   
of carbohydrate ligands (mannosyl di- and trisaccharides) with 
the carbohydrate recognition domain of the lectin DC-SIGN and 
to evaluate their binding modes. 
 
 
 
Fig. 5 Expansion of the NOESY experiments of 2, free (top) and in 
presence of 1 : 50 molar of DC-SIGN (bottom), showing the NOE peaks 
indicative of the conformation of the glycosidic linkages. Experiments 
registered at 500 MHz, in 150 mM NaCl, 20 mM TRIS-d6  4 mM CaCl2 
at 278 K using a mixing time of 600 ms for free and 400 ms in presence of 
DC-SIGN. 
 
The docking study reveals the existence of two potential binding 
sites for disaccharides indicating that only the main binding site, 
which contains the Ca2+ atom, yields stable complexes. This ﬁnding 
is supported by the lack of STD effect in the absence of Ca2+ 
(data not shown). Our study also has disclosed two modes of 
recognition differing in the orientation of the carbohydrate in the 
primary binding site. These modes differ in the terminal hexose 
that is bound to the Ca2+ atom in the main binding site. This 
observation agrees with the crystallographic analysis of DC-SIGN 
with di- and hexasaccharides, containing Mana1,2Man moieties, 
recently solved.14 Our results for the complex with Mana1,2Man, 
have shown that in the main orientation the reducing end of the 
disaccharide binds the Ca2+ and the structure is superimposible 
with the crystallographic one (Fig. 6). Moreover, an alternative 
docking solution points to an additional mode of binding with 
the Ca2+ atom through the reducing end hexose. This mode seems 
similar to the structure of the disaccharide in the minor Man6b 
ligand orientation in the crystallographic study. 
 
Fig. 6 Superimposition of DC-SIGN/Mana1–2Man (1d12) complex 
obtained from the theoretical docking calculation and from the 3D 
structure of disaccharides (pdb code 2it6). Only the binding pocket with 
the representative residues is represented here. 
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Based on the computational analysis, two branched trisaccha- 
rides (Mana1,2[Mana1,6]Man and Mana1,3[Mana1,6]Man) were 
selected as the best candidates to be prepared and studied by 
NMR. These trisaccharides contain as part  of  their  structure 
the 1–2, 1–3 and 1–6 disaccharides presented in high mannose 
structures. Moreover, the Mana1,3[Mana1,6]Man is a key moiety 
of high mannose and it is considered as one of the most 
important trisaccharides interacting with DC-SIGN. On the other 
hand, the trisaccharide Mana1,2[Mana1,6]Man, constitutes part 
of the arabinomannan oligosaccharide and the docking studies 
previewed a better interaction with DC-SIGN probably based on 
a carbohydrate–aromatic interaction with the side chain of Phe 
313. 
The conformational analysis of both trisaccharides reveals that 
the geometry recognized by the receptor is comparable with the 
conformation in the free state and therefore, there are not any large 
conformational changes upon binding. These structures agree in 
essence with those predicted by us using docking or with the 
crystallographic data.14 The docked models of the trisaccharides 
1 and 2 showed that in both cases the non-reducing terminal 
mannoses show interactions with several residues of DC-SIGN 
while the central mannose, ManA, does not. This model is in 
agreement with the STD experiments and indicates that the 
terminal 1–2 or 1–3 linked mannoses have the closest interaction 
with the lectin. This is the hexose that docking structures have 
shown is in contact with the Ca2+ atom on the primary binding 
site. Additionally, this mode of binding, similar to a half moon, is 
somewhat similar to that found for the structure of GlcNAc2Man3 
and DC-SIGN (pdb code 1k9i, see supplementary information). 
On the contrary, terminal mannoses B, 1–6 linked to the central 
one, receive lower levels of magnetization suggesting a looser 
interaction with DC-SIGN. Finally, although the theoretical 
structures predict the lowest interactions for the central residue, 
experimentally this is only true for the trisaccharide 1 but not for 2. 
This observation, together with appreciable differences in the STD 
pattern also indicate potential variations in the binding modes  
of both compounds, probably  as consequence of the existence 
of multiple binding modes as proposed by Seeberger and co- 
workers.14 
These results could be important in the future for the design 
of new ligands for this receptor. In particular, the observation, 
predicted by the docked structures and supported by the experi- 
mental relative STD values, that in both trisaccharides the non- 
reducing end 1–2 or 1–3 linked to the central mannose is the most 
involved in the interaction with the lectin, independent of the 
regiochemistry and relative disposition of the linkage, should be 
considered. Evaluation of the antiviral activity of synthesized di- 
and trisaccharides are being carried out. Very preliminary results 
in an Ebola infection model indicates that trisaccharide 1 presents 
a similar activity to disaccharide Mana1,2Man and less activity 
than trisaccharide 2 (unpublished results). This preliminary data 
are in accordance with our analysis. 
 
Experimental section 
General remarks 
All chemicals were obtained from Aldrich and used without 
further puriﬁcation, unless otherwise noted. 1H and 13C NMR 
were recorded on Bruker Advance DPX 300, and DRX 500 MHz 
spectrometers. Chemical shift are in ppm with respect to TMS 
(tetramethylsilane) using the manufacturer indirect referencing 
method. 2D experiments (COSY, TOCSY, ROESY, and HMQC) 
were done when necessary to assign the oligosaccharide spectra. 
Optical rotations were measured with a Perkin-Elmer 341 po- 
larimeter. Mass spectra were carried out with an Esquire 6000 
ESI-Ion Trap from Bruker Daltonics. 
 
Synthesis of 2-azidoethyl 6-O-tert-butyldiphenylsilyl- 
a-D-mannopyranoside (4) 
To a solution of 3 (945 mg, 3.80 mmol) and imidazole (388 mg, 
5.7 mmol) in dry DMF (10 mL) was added dropwise at room 
temperature TBDPS-Cl (1 mL, 5.7 mmol). The mixture was stirred 
over 4 hours and then concentrated under high vacuum. The 
mixture was diluted in CH2Cl2 (30 mL), washed with water (3 × 
30 mL), dried over MgSO4 and concentrated. The residue was 
puriﬁed by ﬂash chromatography on silica gel (CH2Cl2 : MeOH 
9.5 : 0.5) to give compound 4 as a pale oil (1.46 g, 79%). [a]20 = 
+16.04 (c = 0.75 in CHCl3); 
1H NMR (500 MHz, CDCl3): d = 
7.72–7.68 (m, 4H; HPh), 7.48–7.38 (m, 6H; HPh), 4.85 (d, J = 1.8 Hz, 
1H; H1), 3.97–3.77 (m, 5H; H7 + 2H6 + H4 + H7j), 3.75–3.65 (m, 
1H; H7), 3.60–3.53 (m, 1H; H5), 3.38–3.32 (m, 2H; 2H8), 1.01 (s, 
9H; HTBDPS); 
13C NMR (125 MHz, CDCl3): d      135.6 (CHTBDPS), 
132.8 (CTBDPS), 132.7 (CTBDPS), 129.9 (CTBDPS), 127.9 (CHTBDPS), 
99.7 (C1), 71.5 (C3 or C4), 70.9 (C5), 70.4 (C3 or C4), 66.5 (C7), 
65.2 (C6), 50.5 (C8), 26.8 (CH3TBDPS), 19.2 (CTBDPS); ESI-MS for 
C24H33N3O6Si; calcd: 487.2 M
+; found: 510.2 [M + Na]+; elemental 
analysis calcd (%) for C24H33N3O6Si: C, 59,11%; H, 6,82%; N, 
8,62%; found: C, 59,53%; H, 7,07%; N, 8,74%. 
 
Synthesis of 2-azidoethyl 4-O-benzyl-6-O- 
(tert-butyldiphenylsilyl)-a-D-mannopyranoside (5) 
Mannose derivative 4 (1.17 g, 2.4 mmol), 2,2j-dimethoxypropane 
(2.7 mL) and PPTS (29 mg, 0.11 mmol) were dissolved in acetone 
(20 mL) and the solution was stirred for 24 hours. Et3N was 
added to the reaction mixture and the solvent was removed under 
vacuum. The residue and benzyl bromide (0.45 mL, 3.8 mmol) 
were dissolved in dry DMF (20 mL), and NaH (222 mg, 3.8 mmol) 
was added in small portions at 0 ◦C. The reaction mixture was 
stirred during 12 hours at room temperature. Then, MeOH (1 mL) 
was added to the reaction to quench the excess of NaH and the 
solvent was evaporated. Et2O (100 mL) was added to the reaction 
residue, washed with H2O (2 × 100 mL), dried over MgSO4 and 
concentrated. The residue was dissolved in CH2Cl2 (60 mL) and 
TFA (10 mL) was added to the reaction at room temperature. 
The solution was stirred over 5 hours. A mixture of ice–water at 
0 ◦C was added to the reaction, neutralized with NaHCO3 sat. 
(100 mL), washed with NaHCO3 sat. (2 × 50  mL) and  NaCl  
sat. (100 mL), dried with MgSO4 and the solvent was removed 
under vacuum. The residue was puriﬁed by ﬂash chromatography 
on silica gel (toluene–AcOEt, 9 : 1), to give compound 5 as an 
oil (843 mg, 63% over three steps). [a]20 = +16.02 (c = 0.75 in 
CHCl3); 
1H NMR (300 MHz, CDCl3): d = 7.76–7.68 (m, 4H; 
HTBDPS), 7.47–7.20 (m, 11H; 5HBn and 6HTBDPS), 4.89 (s, 1H; H1), 
4.69 (syst ABBn, 2H), 4.02–3.90 (m, 4H; H2 + H3 + 2H6), 3.85 (dt, 
J = 10.5 and 4.9 Hz, 1H; H7), 3.81–3.65 (m, 2H; H4 and H5), 3.59 
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(dt, J = 10.5 and 4.9 Hz, 1H; H7j), 3.38–3.32 (m, 2H; 2H8), 1.07 
(s, 9H; HTBDPS); 
13C NMR (75 MHz, CDCl3): d = 138.6 (CTBDPS), 
136.3 (CHTBDPS), 136.0 (CHTBDPS), 133.9 (CAr), 133.6 (CAr), 130.1 
(CHAr), 129.0 (CHAr), 128.3 (CHAr), 128.3 (CHAr), 128.1 (CHAr), 
128.1 (CHAr), 128.1 (CHAr), 128.0 (CHAr), 99.9 (C1), 77.6  (C5  or 
C4), 77.2 (CH2Bn), 75.2 (C5 or C4), 72.9 (C2 or C3), 72.0 (C2 or 
C3), 66.7 (C7), 63.5 (C6), 50.9 (C8), 27.2 (CH3TBDPS), 19.7 (CTBDPS); 
ESI-MS for C31H39N3O6Si; calcd: 577.3 M
+; found: 600.3 [M + 
Na]+; elemental analysis calcd (%) for C31H39N3O6Si: C, 64.14%; 
H, 7.07%; N, 6.94%; found: C, 64.45%; H, 6.80%; N, 7.27%. 
 
Synthesis of 2-azidoethyl 4-O-benzyl-3-O-(4-methoxybenzyl)-6-O- 
tert-butyldiphenylsilyl-a-D-mannopyranoside (6) 
A mixture of mannose derivative 5 (850 mg, 1.48 mmol), dibutyltin 
oxide (406 mg, 1.63 mmol) in toluene (40 mL) was reﬂuxed under 
Dean–Stark conditions for 3 h. The reaction mixture was allowed 
to cool to room temperature and DMF (2 mL) was added to 
the mixture. 4-Methoxybenzyl chloride (227 lL, 1.63 mmol) and 
Bu4NI (602 mg, 1.63 mmol) were added, and the mixture was 
heated at reﬂux for 3 h. Then, the mixture was diluted with EtOAc 
(50 mL), washed with H O (2 100 mL) and dried over MgSO . 
129.7 (CAr), 128.5 (CAr), 128.0 (CAr), 127.8 (CAr), 114.0 (CAr), 99.4 
(C1), 79.5 (C3), 75.2 (CH2Bn), 73.8 (C4 or C5), 71.9 (C4 or C5), 71.8 
(CH2PMB), 68.3 (C2), 66.7 (C7), 62.1 (C6), 55.3 (-OCH3), 50.5 (C8); 
ESI-MS for C23H29N3O7; calcd: 459.2 M
+; found: 482.3 [M + Na]+ 
and 498.2 [M + K]+; elemental analysis calcd (%) for C23H29N3O7: 
C, 60.12%; H, 6.36%; N, 9.16%; found: C, 60.15%; H, 6.69%; N, 
9.16%. 
 
Synthesis of 2-azidoethyl 4-O-benzyl-6-O-tert-butyldiphenylsilyl- 
2-O-levulinoyl-3-O-(4-methoxybenzyl)-a-D-mannopyranoside (8) 
Mannose derivative 6 (100 mg, 0.144 mmol) and DCC (149 mg, 
0.720 mmol) were dissolved in CH2Cl2 (2 mL) under argon. After 
addition of levulinic acid (146 lL, 1.44 mmol) a precipitate was 
observed corresponding to the urea formation. A catalytic amount 
of DMAP (8 mg) was added and the reaction was stirred at rt for 
24 h. The reaction mixture was diluted with CH2Cl2 (6 mL), ﬁltered 
over a pad of Celite and concentrated under vacuum. The residue 
was puriﬁed by ﬂash chromatography on silica gel (CH2Cl2 and 
0.5% acetone) to afford 8 as an oil (100 mg, 88%). [a]20 = +2.10 
(c = 0.75 in CHCl3); 
1H NMR (300 MHz, CDCl3): d = 7.76–7.65 
2 × 4 (m, 4H; H ), 7.46–7.30 (m, 6H; H ), 7.30–7.22 (m, 5H; H ), 
The solvent was removed under reduced pressure, followed by ﬂash 
Ph
 Ar Ar 
chromatography on silica gel (toluene–MeOH, 94 : 6), afforded 6 
as an oil (849 mg, 82%). [a]20 = +12.00 (c = 1.00 in CHCl ); 1H 
 
7.21–7.13 (m, 2H; HAr), 6.83 (d, J = 8.7 Hz, 2H; HPMB), 5.39 (dd, 
J  = 1.9 and 2.8 Hz, 1H; H2), 4.89 (d, J  =  10.6 Hz, 1H; CH2Bn), 
D 4.87 (s, 1H; H ), 4.62 (d, J  = 10.9 Hz, 1H; CH ), 4.57 (d, J = 
1 NMR (300 MHz, CDCl ): d = 7.78–7.66 (m, 4H; 4H ), 7.47– 2PMB 
3 TBDPS 
7.23 (m, 11H; 2HPMB and 9HAr), 6.87 (d, J = 8.6 Hz, 2H; 2HPMB), 10.7 Hz, 1H; CH2Bn), 4.45 (d, J = 10.9 Hz, 1H; CH2PMB), 4.03– 
4.94 (d, J = 1.0 Hz, 1H; H ), 4.84 (d, J = 10.9 Hz, 1H; CH ), 4.63 3.87 (m, 4H; H3 + H5 + 2H6), 3.87–3.77 (m, 4H; -OCH3 and H7j), 
1 2Bn 3.74–3.66 (m, 1H; H ), 3.58 (dt, J = 10.6 and 5.1 Hz, 1H; H ), 3.34 
(s, 2H; CH2PMB) 4.55 (d, J = 10.9 Hz, 1H; CH2Bn), 4.09–4.04 (m, 1H; 
4 7 
(t, J = 5.1 Hz, 2H; 2H ), 2.83–2.61 (m, 4H; CH CH ), 2.51 (s, 
   
H2), 3.97–3.84 (m, 4H; H3 + 2H6 + H7j), 3.84–3.77 (m, 4H; H4 + 
-OCH ), 3.77–3.69 (m, 1H; H ), 3.65–3.55 (m, 1H; H ), 3.44–3.27 
   
3H; CH3lev), 1.56 (s, 9H; CHTBDPS); 
13C NMR (75 MHz, CDCl3): 
3 5 7 
(m, 2H; 2H ), 1.05 (s,  9H; H ); 13C NMR (75 MHz, CDCl ): d = 206.8 (COlev), 172.6 (COOlev), 159.7 (CAr), 136.3 (CAr), 136.0 
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133.7 (C ), 130.4 (C ), 130.1 (C ), 130.0 (C ), 128.8 (C ), 128.3 128.3 (CAr), 128.1 (CAr), 128.0 (CAr), 114.2 (CAr), 98.2 (C1), 78.1 
Ar Ar Ar Ar Ar (C ), 75.7 (CH ), 74.3 (C ), 73.3 (C ), 71.8 (CH ), 69.3 (C ), 
(C ), 128.1 (C ), 128.0 (C ), 114.4 (C ), 99.6 (C ), 80.2 (C ), 74.4 
3
 2Bn 5 4 2PMB 2 
Ar Ar Ar 
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6 
(CH   ), 28.5 (−CH   ), 27.2 (CH ), 19.8 (C ); ESI-MS for 
3 8 3TBDPS TBDPS C H N O Si; calcd: 795.4 M+; found: 818.3 [M + Na]+; elemental 
for C H N O Si; calcd: 697.3 M+; found: 720.3 [M + Na]+ and 44 53 3 9 
39 47 3 7 analysis calcd (%) for C H N O Si: C, 66.39%; H, 6.71%; N, 
736.3 [M + K]+; elemental analysis calcd (%) for C H N O Si: 44 53 3 9 
39 47 3 7 
C, 66.96%; H, 6.80%; N, 5.74%; found: C, 67.12%; H, 6.79%; N, 
6.02%. 
Synthesis of 2-azidoethyl 4-O-benzyl-3-O-(4-methoxybenzyl)- 
a-D-mannopyranoside (7) 
Mannose derivative 6 (700 mg, 1.00 mmol) and TBAF (533 mg, 
2.00 mmol) were dissolved in THF (7 mL). The solution was 
stirred under argon during 5 hours at room temperature. The 
solvent was removed under vacuum and the residue was puriﬁed 
by ﬂash chromatography on silica gel (hexane–AcOEt, 1 : 2), to 
give compound 7 as an oil (436 mg, 95%). [a]20 = +34.5 (c = 0.75 
in CHCl3); 
1H NMR (500 MHz, CDCl3): d = 7.33–7.24 (m, 6H; 
HAr), 6.84 (d, 2H; 2HPMB), 4.90 (d, J = 1.5 Hz, 1H; H1), 4.86 (d,  
J = 11.0 Hz, 1H; CH2PMB), 4.63 (d, J = 11.0 Hz, 1H; CH2PMB), 
4.60 (s, 2H; CH2Bn), 4.01 (dd, J = 1.5 and 3.1 Hz, 1H; H2), 3.88 
(dd, J = 3.1 and 9.0 Hz, 1H; H3) 3.86–3.79 (m, 3H; H4 and 2H6), 
3.78 (s, 3H; -OCH3), 3.75 (dd, J = 3.9 and 12.3 Hz, 1H; H7j), 
3.58 (dt, J = 3.9 and 9.9 Hz, 1H; H7), 3.40–3.29 (m, 2H; 2H8); 
13C 
NMR (CDCl3, 125 MHz): d = 159.5 (CAr), 138.2 (CAr), 129.9 (CAr), 
5.28%; found: C, 66.27%; H, 6.87%; N, 5.08%. 
 
Synthesis of 2-azidoethyl 4-O-benzyl-2-O-levulinoyl-3-O-(4- 
methoxybenzyl)-a-D-mannopyranoside (9) 
Acetic acid (150 lL) was added slowly to a solution of 8 (215 mg, 
0.270 mmol) in dry THF (2 mL), under nitrogen at 0 ◦C. The 
solution was warmed up to room temperature and TBAF 1 M in 
THF (330 lL, 0.33 mmol) was added to the solution. The solution 
was stirred overnight and then the solvent was removed under 
vacuum. The residue was puriﬁed by ﬂash chromatography on 
silica gel (hexane–AcOEt, 1 : 2) to give compound 9 as an oil 
(150 mg, quant.). [a]20 = +13.02 (c = 0.4 in CHCl3); 
1H NMR 
(300 MHz, CDCl3): d = 7.38–7.21 (m, 7H; 5HBn and 2HPMB), 6.84 
(d, J = 8.7 Hz, 2H; 2HPMB), 5.34 (dd, J = 3.1 and 1.8 Hz, 1H; 
H2), 4.90 (d, J = 10.9 Hz, 1H; CH2Bn), 4.86 (d, J = 1.6 Hz, 1H; 
H1), 4.61 (d, J = 10.9 Hz, 1H; CH2Bn), 4.61 (d, J = 10.9 Hz, 
1H; CH2Bn), 4.45 (d, J = 10.9 Hz, 1H; CH2Bn), 4.00 (dd, J = 3.3 
and 9.1 Hz, 1H; H3), 3.89–3.66 (m, 5H; H4 + H5 + 2H6 + H7), 
3.59 (dt, J = 10.3 and 4.9 Hz, 1H; H7j), 3.37 (t, J = 4.9 Hz, 2H; 
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2H8), 2.87–2.57 (m, 4H; CH2CH2lev), 2.18 (s, 3H; CH3lev); 
13C NMR 
(75 MHz, CDCl3): d = 206.9 (COlev), 172.5 (COOlev), 159.7 (CPMB), 
138.6 (CAr), 130.4 (CAr), 130.2 (CAr), 128.9 (CAr), 128.5 (CAr), 128.3 
(CAr), 114.2 (CAr), 98.2 (C1), 77.8 (C3), 75.6 (CH2Bn), 74.2  (C4  or 
C5), 72.5 (C4 or C5), 71.8 (CH2Bn), 69.2 (C2), 67.2 (C7), 62.5 (C6), 
55.7 (-OCH3), 50.8 (C8), 38.5 (CH2lev), 30.2 (CH3lev), 28.5 (CH2lev); 
ESI-MS for C28H35N3O9; calcd: 557.2 M
+; found: 596.1 [M + Na]+ 
and 580.1 [M + K]+; elemental analysis calcd (%) for C28H35N3O9: 
C, 59.66%; H, 6.12%; N, 7.73%; found: C, 59.84%; H, 6.00%; N, 
7.74%. 
 
Synthesis of 2-azidoethyl 4-O-benzyl-2-O-levulinoyl- 
a-D-mannopyranoside (10) 
Mannose derivative 9 (74 mg, 0.126 mmol) was dissolved in 
CH2Cl2 (5 mL), the solution was cooled at  20 ◦C and TFA  
(1.5 mL) was added to the solution. The reaction mixture was 
stirred during 20 min. Then, ethanol (0.5 mL) and CH2Cl2        
(4 mL) were added to the reaction. The solution was washed 
with NaHCO3 sat. (2 × 10 mL), NaCl sat. (10 mL), and dried 
with MgSO4. The solvent was removed under vacuum and the 
residue was puriﬁed by ﬂash chromatography on silica gel (hexane– 
AcOEt, 2 : 1) to give compound 10 as and oil (53 mg, 97%). [a]20 = 
3.5 Hz and 1.5 Hz, 1H; H2), 5.22–5.18 (m, 2H; H2  and H1),  5.03 
(d, J = 1.5 Hz, 1H; H1), 4.89 (d, J = 11.0 Hz, 1H; 1HBn), 4.86 (d, 
J = 11.0 Hz, 1H; 1HBn), 4.79 (s, 2H; 2HBn), 4.75 (d, J = 11.0 Hz, 
1H; 1HBn), 4.73 (d, J = 11.0 Hz, 1H; 1HBn), 4.72 (d, J = 11.0 Hz, 
1H; 1HBn), 4.69 (d, J = 1.5 Hz, 1H; H1), 4.62–4.47 (m, 7H; 7HBn), 
4.24 (dd, J  = 3.8 Hz and 9.4 Hz, 1H; H3), 4.01–4.67 (m, 15H;    
H4A, H5A, 2H6A, H3B, H4B, H5B, 2H6B, H3C, H4C, H5C, 2H6C and H7), 
3.56–5.51 (m, 1H; H7), 3.33–3.27 (m, 2H; 2H8), 2.74–2.61 (m, 4H; 
2 × -CH2lev), 2.20 (s, 3H; CH3lev), 2.15 (s, 3H; -OOCCH3), 2.13 (s, 
3H; -OOCCH3); 
13C NMR (125 MHz, CDCl3): d = 208.1 (C=O), 
174.5 (C=O), 172.6 (C=O), 172.4 (C=O), 141.0 (CAr), 140.7 (CAr), 
140.5 (CAr), 140.3 (CAr), 140.2 (CAr), 139.9 (CAr), 130.7 (CAr),130.7 
(CAr), 130.6 (CAr), 130.5 (CAr), 130.4 (CAr), 130.3 (CAr), 130.2 (CAr), 
130.1 (CAr), 130.0 (CAr), 129.8 (CAr), 129.7 (CAr), 102.4 (C1), 100.9 
(C1), 99.4 (C1), 80.2, 80.0, 76.7, 76.5, 76.3, 75.7, 75.7, 74.6, 74.2, 
74.1, 73.8, 73.6, 71.1, 71.0, 70.8, 70.7, 69.0, 67.6 (C2A + C3A + 
C4A + C5A + C6A, C2B +C3B + C4B + C5B + C6B  + C2C  + C3C  + C4C  + 
C5C + C6C) 52.5 (C8), 40.1 (CH2lev), 32.0 (CH2lev), 30.3 (CH3lev), 23.4 
(OCOCH3), 23.3 (OCOCH3); ESI-MS for C78H87N3O20; calcd: 
1385,6 M+; found: 1408.6 [M + Na]+ and 1424.4 [M + K]+. 
 
Synthesis of 2-azidoethyl O-(2-O-acetyl-3,4,6-tri-O-benzyl- 
a-D-mannopyranosyl-(1→2)-O-[2-O-acetyl-3,4,6-tri-O- 
+32.91 (c = 0.70 in CHCl3); 
1H NMR (300 MHz, CDCl3): d = 
7.40–7.31 (m, 4H; 4HBn), 7.31–7.25 (m, 1H; HBn), 5.13 (dd, J  = 2.0 
and 3.3 Hz, 1H; H2), 4.87 (d, J = 10.9 Hz, 1H; CH2Bn), 4.82 (d, J = 
1.2 Hz, 1H; H1), 4.71 (d, J = 10.9 Hz, 1H; CH2Bn), 4.19–4.13 (m, 
1H; H3), 3.89–3.76 (m, 3H; 2H6 and H7j), 3.75–3.64 (m, 2H; H4 
and H5), 3.61–3.55 (m, 1H; H7), 3.42–3.32 (m, 2H; 2H8), 2.84–2.75 
(m, 2H; CH2lev), 2.67–2.59 (m, 2H; CH2lev), 2.19 (s, 3H; CH3lev); 
13C 
NMR (75 MHz, CDCl3): d = 207.1 (COlev), 170.1 (COOlev), 133.7 
(CAr), 133.2 (CAr), 130.6 (CAr), 129.6 (CAr), 127.5 (CAr), 127.4 (CAr), 
97.5 (C1), 75.7 (C4 or C5), 72.7 (C2), 72.0 (C4 or C5), 70.1 (C-3), 66.6 
(C7), 61.7 (C6), 50.4 (C8), 38.4 (CH2lev), 29.7 (CH3lev), 28.4 (CH2lev); 
ESI-MS for C20H27N3O8; calcd: 437.2 M
+; found: 460.2 [M + Na]+; 
elemental analysis calcd (%) for C20H27N3O8: C, 53.90%; H, 5.95%; 
N, 9.92%; found: C, 53.99%; H, 5.75%; N, 10.14%. 
 
Synthesis of 2-azidoethyl O-(2-O-acetyl-3,4,6-tri-O-benzyl-a-D- 
mannopyranosyl-(1→3)-O-[2-O-acetyl-3,4,6-tri-O-benzyl- 
a-D-mannopyranosyl-(1→6)]-4-O-benzyl-2-O-levulinoyl- 
a-D-mannopyranoside (11) 
Mannose derivative 10 (40 mg, 0.092 mmol), and the glycosyl 
donor 13 (146 mg, 0.249 mmol) were dissolved in dry CH2Cl2 
(2  mL)  in  the  presence  of  4  A˚   molecular  sieves.  The  mixture 
was stirred during 2 hour at room temperature under argon 
atmosphere. Then, the system was cooled at  20 ◦C, NIS (56 mg, 
0.249 mmol) and TfOH (2.5 lL, 0.026 mmol) were added and the 
mixture was stirred during 20 min. The reaction was monitored by 
TLC (toluene–MeOH, 9 : 1) and when it was completed, NaHCO3 
sat. (50 lL) was added to quench the TfOH. The reaction mixture 
was diluted with CH2Cl2 (6 mL), ﬁltered over a pad of Celite, 
washed with Na2S2O3 sat., dried over MgSO4 and the solvent 
was removed under vacuum. The residue was puriﬁed by ﬂash 
chromatography on silica gel (hexane : AcOEt, 7 : 1) to give 
compound 11 as an oil (91 mg, 72%). [a]20 = +45.76 (c = 1.00 
in CHCl3); 
1H NMR (500 MHz, CDCl3): d = 7.47–7.16 (m, 32H; 
HArBn), 5.49 (dd, J = 3.5 Hz and 1.5 Hz, 1H; H2), 4.47 (dd, J = 
benzyl-a-D-mannopyranosyl-(1→6)]-4-O-benzyl- 3-
O-(4-methoxybenzyl)-a-D-mannopyranoside (12) 
Mannose derivative 7 (49 mg, 0.107 mmol), and the glycosyl donor 
13 (163 mg, 0.278 mmol) were dissolved in dry CH2Cl2 (2 mL) in 
the  presence  of  4  A˚   molecular  sieves.  The  mixture  was  stirred 
during 2 hours at room temperature under argon atmosphere. 
Then, the system was cooled at 20 ◦C, NIS (63 mg, 0.278 mmol) 
and TfOH (2.5 lL, 0.026 mmol) were added and the mixture 
was stirred during 20 min. The reaction was monitored by TLC 
(toluene–MeOH, 9 : 1) and when it was completed, NaHCO3 sat. 
(50 lL) was added to quench the TfOH. The reaction mixture was 
diluted with CH2Cl2 (6 mL), ﬁltered over a pad of Celite, washed 
with Na2S2O3 sat., dried over MgSO4 and the solvent was removed 
under vacuum. The residue was puriﬁed by ﬂash chromatography 
on silica gel (hexane : AcOEt, 7 : 1) to give compound 12 as an 
oil (88 mg, 70%). [a]20 = +17.05 (c = 1.00 in CHCl3); 
1H NMR 
(500 MHz, CDCl3): d = 7.32–7.21 (m, 32H; 18HArBn + 2HArPMB), 
7.16–7.13 (m, 2H; 2HArBn), 7.12–7.08 (m, 2H; 2HArBn), 6.80 (d, J = 
9.0 Hz, 2H; 2HArPMB), 5.51 (dd, J  = 3.5 Hz and 1.5 Hz, 1H; H2B), 
5.34 (dd, J = 2.0 Hz and 3.0 Hz, 1H; H2C), 4.99 (d, J = 1.5 Hz, 1H; 
H1B), 4.89 (d, J = 1.5 Hz, 1H; H1C), 4.82 (d, J = 11.0 Hz, 1H; HBn), 
4.81 (d, J = 11.0 Hz, 2H; 2HBn), 4.81 (d, J = 1.5 Hz, 1H; H1A), 4.79 
(d, J = 11.0 Hz, 1H, HBn), 4.61 (d, J = 11.0 Hz, 1H; HBn), 4.61 (d, 
J = 11.0 Hz, 1H; HBn), 4.56 (s, 2H; 2HBn), 4.50 (d, J = 11.0 Hz, 1H; 
HBn), 4.49 (d, 1H, J = 11.0 Hz, 1H; HBn), 4.46–4.40 (m, 5H, 5HBn), 
3.95 (dd, 1H J = 3.2 Hz and 9.3 Hz, 1H; H3A), 3.94–3.60 (m, 15 H; 
H2A, H4A, H5A, 2H6A, H3B, H4B, H5B, 2H6B, H3C, H4C, H5C and 2H6C), 
3.76 (s, 3H, -OCH3), 3.52 (t, J  = 9.3 Hz, 1H; H7), 3.32–3.28 (m, 
1H; H7), 3.20–3.11 (m, 2H; 2H8), 2.10 (s, 3H; -OOCCH3), 2.09 (s, 
3H; -OOCCH3); 
13C NMR (100 MHz, CDCl3): d = 170.3 (C=O), 
170.07 (C=O), 159.2 (CAr), 138.6 (CAr), 138.4 (CAr), 138.3  (CAr), 
138.2 (CAr), 138.0 (CAr), 137.9 (CAr), 130.3 (CAr), 129.3 (CAr), 128.4 
(CAr), 128.3 (CAr), 128.3 (CAr), 128.2 (CAr), 128.1 (CAr), 128.0 (CAr), 
128.0 (CAr), 127.9 (CAr), 127.8 (CAr), 127.6 (CAr), 127.6 (CAr), 127.5 
(CAr), 113.8 (CAr), 99.8 (C1), 98.7 (C1), 97.1 (C1), 79.4, 78.1, 78.0, 
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77.2, 75.2, 75.1, 74.9, 74.4, 73.5, 73.4, 71.9, 71.5, 71.4, 70.8, 69.2, 
68.7, 68.5, 68.5, 66.3, 55.2 (C2A + C3A + C4A  + C5A +  C6A +  C2B  + 
C3B + C4B + C5B + C6B + C2C + C3C  + C4C  + C5C  + C6C  + C7), 50.3 
(C8), 21.1 (OCOCH3), 21.1 (OCOCH3); ESI-MS for C81H89N3O19; 
calcd: 1407.6 M+; found: 1446.6 [M + K]+. 
 
Synthesis of 2-aminoethyl O-a-D-mannopyranosyl(1→2)[O-a-D- 
mannopyranosyl(1→6)]-a-D-mannopyranoside (1) 
The protected trisaccharide 12 (70 mg, 0.06 mmol) was dissolved 
in dry MeOH (1 mL) and NaOMe solution (1 M in MeOH) (60 ll, 
0.06 mmol) was added. The reaction mixture was stirred at room 
temperature for 30 min. Then, the mixture was neutralized with 
Amberlite IR 120 resin, ﬁltered and the solvent was removed under 
vacuum. The white solid was dissolved in MeOH (3 mL), Pd–C 
10% (cat.) was added and the reaction mixture was hydrogenated 
under H2 (1 bar) until reduction was complete (monitored by TLC 
i-PrOH : H2O 7 : 3 + 1% AcOH) to give trisaccharide 1 as a white 
solid (32 mg, 98% over two steps). [a]20 = +78.2 (c = 0.50 in H2O); 
1H NMR (500 MHz, D2O): d = 5.10 (s, 1H; H1A), 5.00 (s, 1H; 
H1C), 4.90 (s, 1H; H1B), 4.06 (m, 1H; H2C), 3.99 (m, 1H; H2A), 3.97 
(m, 1H; H6A), 3.96 (m, 1H; H2B), 3.91 (m, 1H; H3A), 3.90 (m, 1H; 
H7), 3.87 (m, 1H; H6C), 3.81 (m, 1H; H4A), 3.80 (m, 1H; H3B), 3.77 
(m, 1H; H3C), 3.73 (m, 1H; H6A), 3.73 (m, 1H; 2H6B), 3.72 (m, 1H; 
suite.26 The starting coordinate of human DC-SIGN was taken 
from the Protein Data Bank with  code  1k9i.12  The  structure 
was edited to contain only one protein monomer together with 
calcium ions, protein hydrogen atoms were added, the partial 
charges were calculated using AMBER27,28 procedure as imple- 
mented in SYBYL and the calcium ions were given a charge of 
(+2). Atom types and charges for oligosaccharides were deﬁned 
using the PIM parameters developed for carbohydrates.29 All 
ligand structures were obtained from different protein complex: 
dimannoside Mana1,2Man (ManC-ManA) from 1i3h;30 diman- 
nosides Mana1,3Man (ManD-ManA) and Mana1,6Man (ManB- 
ManA), trimannoside Mana1,2[Mana1,6]Man, (ManC-ManA- 
ManB) were built from Mana1,2Man using the Sketch module 
of SYBYL; and trimannoside Mana1,3[Mana1,6]Man (ManD- 
ManA-ManB) was built and ﬁtted into DC-SIGN using the 
correspond ligand (GlcNAc2Man3) from 1k9i. 
The  nomenclature  used  for  the  theoretical  complex  (1d13, 
1d12, 1d16, 1t26, 1t36)  does  mention  if  it  is  a  dimanno- 
side  (d)  a  trimannoside  (t)  and  the  glycoside  bond  1    3, 
1 2, 1 6 in Mana1,3Man, Mana1,2Man and Mana1,6Man, 
respectively and, 1 2–6 1, 1 3–6 1 in the trisaccharide 
Mana1,2[Mana1,6]Man and Mana1,3[Mana1,6]Man. The dihe- 
dral angles U, w and x are deﬁned, following IUPAC  deﬁnition, 
H5A ), 3.71 (m, 1H; H5C ), 3.69 (m, 1H; H6C ), 3.65 (m, 1H; H7), 3.65 
as O5–C1–O1–Cxj , C1–O1–Cxj –Cx + 1j and O5–C5–C6–O6 respec- 
tively, where Cxj and Cx + 1j are the aglyconic atoms. For a-D-Manp- 
(m, 1H; H5B), 3.64 (m, 1H; H4B), 3.61 (m, 1H; H4C), 3.17 (m, 1H; 
2H8). 13C NMR (125 MHz, D2O): d = 102.4 (C1C), 99.5 (C1B), 98.4 
(C1A), 78.7 (C2A), 73.3 (C5C), 72.8 (C5B), 70.5 (C3B), 70.5 (C3C), 71.4 
(C5A), 70.1 (C3A), 69.9 (C2C), 69.9 (C2B), 66.7 (C4C), 66.6 (C4B), 66.4 
(C4A), 65.1 (C6A), 64.5 (C7), 61.0 (C6C), 60.9 (C6B), 39.1 (C8). 
 
Synthesis of 2-aminoethyl O-a-D-mannopyranosyl(1→3)[O-a-D- 
mannopyranosyl(1→6)]-a-D-mannopyranoside (2) 
The protected trisaccharide 11 (70 mg, 0.05 mmol) was dissolved 
in dry MeOH (2 mL) and NaOMe solution (1 M in MeOH) (50 ll, 
0.05 mmol) was added. The reaction mixture was stirred at room 
temperature for 30 min. Then, the mixture was neutralized with 
Amberlite IR 120 resin, ﬁltered and the solvent was removed under 
vacuum. The white solid was dissolved in MeOH (3 mL), Pd–C 
10% (cat.) was added and the reaction mixture was hydrogenated 
under H2 (1 bar) until reduction was complete (monitored by TLC 
i-PrOH : H2O 7 : 3 + 1% AcOH) to give trisaccharide 2 as a white 
solid (27 mg, 97% over two steps). [a]20 = +84.0 (c = 0.50 in H2O);
 
1H NMR (500 MHz, D2O): d = 5.10 (m, 1H; H1B), 4.90 (s, 1H; 
H1D), 4.85 (s, 1H; H1A), 4.15 (m, 1H; H2A), 4.06 (m, 1H; H2B), 4.00 
(m, 1H; H6A), 3.98 (m, 1H; H2D), 3.96 (m, 1H; H7), 3.93 (m, 1H; 
H3A), 3.92 (m, 1H; H4A), 3.89 (m, 1H; H6A), 3.87 (m, 1H; H3B), 3.82 
(m, 1H; H3D), 3.79 (m, 1H; H5A), 3.77 (m, 1H; H5B), 3.75 (m, 1H; 
H6A), 3.75 (m, 1H; H6D), 3.70 (m, 1H; H6A), 3.70 (m, 1H; H7), 3.67 
(m, 1H; H4D), 3.66 (m, 1H; H5D), 3.61 (m, 1H; H4B), 3.24 (m, 1H; 
2H8); 
13C NMR (125 MHz, D2O): d = 102.4 (C1B), 99.8 (C1A), 99.3 
(C1D), 78.5 (C3A), 73.4 (C5B), 72.6 (C5D), 71.1 (C5A), 70.7 (C3D), 70.3 
(C3B),70.1 (C2B), 70.0 (C2D), 69.4 (C2A), 66.6 (C4D), 66.6 (C4B), 65.3 
(C4A), 65.2 (C6A), 63.6 (C7),60.8 (C6D), 60.8 (C6B), 39.1 (C8). 
 
Computational studies 
All calculations were performed on a Silicon Graphics Octane 
workstation (R12000, 300 MHz) using the SYBYL 6.9 program 
(1–6)-a-D-Manp, the U is deﬁned as O5–C1–O1–C6j, w C1–O1– 
C6j–C5j and x O1–C6j–C5j–ORj where ORj is the endocyclic ring 
oxygen. 
To build the complexes, the ligands were ﬁrst manually po- 
sitioned within the binding pocket of the protein taking into 
account the experimental data about the binding of 1k9i. Two 
binding modes were examined for each of the disaccharides 
Mana1,6Man and Mana1,2Man: one refers to the primary 
binding site (complexes 1d12 and 1d16, respectively), which cor- 
responds to the glycosidic bonds at the 3-position (Mana1,3Man 
in the pentasaccharide GlcNAc2Man3; ManD-ManA), and the 
other involves the secondary binding site (complexes 2d12 and 
2d16, respectively), corresponding to the glycosidic bonds at 6- 
position (Mana1,6Man in the pentasaccharide GlcNAc2Man3: 
ManB-ManA). Regarding the disaccharide Mana1,2Man, it was 
only considered the primary binding site (1d13). Subsequent 
energy minimization was performed using the AMBER99 force 
ﬁeld with geometry optimization of the sugar and the side chains 
of the protein. Energy minimizations were  carried  out  using 
the Conjugate Gradient procedure until a gradient deviation of 
0.005 kcal mol−1 A˚ −1 was attained. A distance-dependent dielectric 
constant was used in the calculations. 
These complexes were used as input structure for docking 
studies using FlexiDock command in the Biopolymer module. 
FlexiDock software performs ﬂexible docking of conformationally 
ﬂexible ligands into receptor binding sites and provides control of 
ligand binding characteristics, taking into account rigid, partially 
ﬂexible, or fully ﬂexible receptor side chains. FlexiDock incorpo- 
rates the Van der Waals, electrostatic, torsional and constraint 
energy terms of the Tripos force ﬁeld, and it uses a genetic 
algorithm to determine the optimum ligand geometry. Genetic 
algorithms31 (GA) borrow methodology and terminology from 
biological (or Darwinian) evolution, in which they are an iterative 
process where the most-ﬁt members of a population will have the 
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best chance of propagating themselves into future generations. 
During the ﬂexible docking analysis the residues involved in the 
binding site (sphere of 7 A˚  around the ligand), and the ligands were 
considered ﬂexible. The default SYBYL FlexiDock parameters 
were utilized in all cases. Five runs of FlexiDock were performed 
searching for the different binding modes with iterations set to 
500–1000 generations per gene, where gene is the number of 
rotatable bonds plus six, obtaining a series of model complexes. 
The output complexes of FlexiDock were analyzed on the basis 
of the score provided by FlexiDock, the dihedral angles U, w, x 
and the distances of key residues. The conformations with typical 
dihedral angles of each glycosidic bond at positions 2, 3, and 6 
were clustered and the rest of the non-typical conformations were 
eliminated. A member of each family was energy minimized. These 
output complexes were again optimized until gradient 0.01 kcal 
mol−1 A˚ −1 using the above mentioned conditions, the conformation 
with the lowest score and fulﬁlling the experimental requirements 
being chosen. The binding free energies (DGbind) of all disaccharides 
and trisaccharides complexes were calculated with the Structural 
Thermodynamics Calculations V4.3 (STC)  program32  in  order 
to predict the interaction energy of each complex. The STC 
program  calculates  the  DGbind  from  a  parameterization  (per  A˚ 
2 
of polar and nonpolar ASA) of the heat capacity, enthalpy, and 
solvation entropy obtained from a global ﬁt of structural and 
thermodynamic database of globular proteins. Carbohydrate– 
protein interactions were calculated with the LPC program.33 As 
selection criteria used to identify C–H p interaction, we applied 
those used by Brandl34 and Kerzmann.35 Fig. 7 shows the three 
values dcx, achx and dHpX. The limits are dcx< 4.5 A˚ , achx > 110◦ and 
dHpX < 2.0 A˚ . 
 
Fig. 7 Geometry of the C–H ··· p interaction. 
 
NMR 
NMR sample preparation. NMR experiments were recorded 
in AVANCE Bruker instruments operating at 500.13 MHz, at  
288 K. Samples of free 1 and 2 were prepared in 150 mM NaCl, 
25 mM d-TRIS (pH* 8.1) in D2O after three cycles of deuterium 
exchange by evaporation and resolution of the trisaccharide in 
D2O. The samples in the presence of DC-SIGN EC were prepared 
using 2 mM of carbohydrate and 40 lM of lectin, assuming a 
monomeric state, in D2O (150 mM NaCl, 25 mM d-TRIS, pH* 
8.1). 
NMR experiments were performed using manufacturer pulse 
sequences: dqf-COSY,36 TOCSY,37 NOESY,38 ROESY,39 and 
HSQC40 implemented with z-pulsed ﬁeld gradients when possible, 
and acquired using time proportional phase incrementation 
mode.41 The size of the acquisition data matrix for homonuclear 
experiments was typically of 2k 512 in F2 and F1 dimensions, 
respectively. Data were processed using manufacturer software, 
raw data were multiplied by shifted square sine window function 
prior to Fourier transform, and the baseline was corrected using 
polynomial ﬁtting. 
STD experiments were performed at 278  K  using  water-  
gate solvent suppression at 0.5, 0.75, 1.0, 1.25, 1.5 and 2.0 s 
saturation times using a  train  of  Gaussian  shaped  pulses  of  
49 ms and 100–60 Hz power spaced by 1.0 ms delays.23 On- 
resonance irradiation was performed at 0.9 ppm, appropriate 
blank experiments were also performed to assure the absence of 
direct irradiation on the ligand. 
 
DC-SIGN EC expression and puriﬁcation 
Plasmids pET30b (Novagen) containing cDNA encoding the 
EctoDomain ECD (corresponding to amino acids 66–404) of 
DC-SIGN were used for overproduction as described previously.5 
Proteins produced in inclusion bodies have been refolded as 
already described.42 Puriﬁcation of functional DC-SIGN proteins 
were achieved by an afﬁnity chromatography on Mannan-agarose 
column (Sigma) equilibrated in 25 mM Tris-HCl pH 7.8, 150 mM 
NaCl, 4 mM CaCl2 (Buffer A) and eluted in  same  buffer 
lacking CaCl2 but supplemented with 10 mM EDTA. This step 
was followed by a superose 6 size exclusion chromatography 
equilibrated in buffer A. Protein was concentrated to 9 mg ml−1 and 
dialysed three times against the deuterated buffer 25 mM Tris DCl, 
150 mM NaCl, 4 mM CaCl2 at pD 7.8 in D2O (deuterated Tris- 
d11 (98%) was purchased from Cambridge Laboratories Inc. and 
the D2O from Spectra Stable Isotopes). Protein was then stored in 
liquid nitrogen. 
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